Clinical trials in Montpellier – page 90

1 099 clinical trials in Montpellier, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Montpellier at a glance

1 099

clinical trials

Research sites4

Quick filters

1 099 trials in Montpellier

Open in trial search

Hormone receptor positive breast cancer+1

Not recruiting

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Antipsychotics
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Kite Pharma Inc.

Contact Research Centre

Diffuse large B-cell lymphoma+1

Not recruiting

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Bronchiectasis

Not recruiting

Study on Long-Term Safety and Efficacy of BI 1291583 in Patients with Bronchiectasis

Registered drug

Study on Long-Term Safety and Efficacy of BI 1291583 in Patients with Bronchiectasis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:BI 1291583
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Secondary progressive multiple sclerosis

Not recruiting

Study on Stopping Disease-Modifying Therapies in Inactive Secondary Progressive Multiple Sclerosis Patients Over 50 Using Glatiramer Acetate and Drug Combination

Registered drugNo placebo

Study on Stopping Disease-Modifying Therapies in Inactive Secondary Progressive Multiple Sclerosis Patients Over 50 Using Glatiramer Acetate and Drug Combination

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Centre Hospitalier Universitaire De Rennes

Contact Research Centre

Colon cancer

Not recruiting

Comparison of drug combinations containing irinotecan, oxaliplatin, fluorouracil and folinic acid for treatment of high-risk stage III colon cancer

Registered drugNo placebo

Comparison of drug combinations containing irinotecan, oxaliplatin, fluorouracil and folinic acid for treatment of high-risk stage III colon cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Unicancer

Contact Research Centre

Ovarian cancer+1

Not recruiting

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

Registered drugNo placebo

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:MPS-102
Sponsor:Arcagy Gineco

Contact Research Centre

Renal cancer metastatic

Not recruiting

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Exelixis Inc.

Contact Research Centre

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Letrozole
Sponsor:Pfizer Inc.

Contact Research Centre

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Dimethyl Fumarate for Children Aged 10-17 with Relapsing-Remitting Multiple Sclerosis

InvestigationalNo placebo

Study on the Safety and Effectiveness of Dimethyl Fumarate for Children Aged 10-17 with Relapsing-Remitting Multiple Sclerosis

InvestigationalNo placebo

France

Participants:0–17 years
Substances:Dimethyl Fumarate
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Elexacaftor
Sponsor:Vertex Pharmaceuticals Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Montpellier

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, bladder cancer, and mantle cell lymphoma. Studies evaluate combination therapies and novel treatment approaches for improved patient outcomes.

Advanced HNSCC Treatment Combinations
Non-muscle Invasive Bladder Cancer Therapy
Gastric Cancer Targeted Treatments

Research includes evaluation of immunotherapy combinations and targeted molecular approaches.

02 Autoimmune Conditions

Studies examining innovative treatments for Crohn's disease, multiple sclerosis, and systemic sclerosis. Research focuses on novel therapeutic approaches and treatment optimization.

Fecal Microbiota Transplantation Studies
MS Treatment De-escalation Strategies
Advanced Autoimmune Therapies

Trials aim to improve disease management and patient quality of life.

03 Rare Diseases

Investigating treatments for achondroplasia, pyruvate dehydrogenase deficiency, and thyroid eye disease. Focus on developing targeted therapies for these uncommon conditions.

Growth Disorders in Children
Metabolic Disease Management
Innovative Therapeutic Approaches

Research aims to address unmet medical needs in rare disease populations.

04 Preventive Medicine

Clinical trials evaluating vaccines for cytomegalovirus, yellow fever, and HPV prevention. Studies focus on immunization effectiveness and safety profiles.

Vaccine Development Programs
Infection Prevention Strategies
Population Health Protection

Research emphasizes disease prevention and public health improvement.

Back to France All countries